Rare Diseases: Drugs

Department of Health and Social Care written question – answered on 6th November 2018.

Alert me about debates like this

Photo of Viscount Waverley Viscount Waverley Crossbench

To ask Her Majesty's Government what steps they are taking to reduce any disparity in access to rare disease medicines between England, Wales, Scotland and Northern Ireland.

Photo of Viscount Waverley Viscount Waverley Crossbench

To ask Her Majesty's Government what steps they are taking to reduce any disparity in access to rare disease medicines in England compared with economically similar countries in Europe.

Photo of Viscount Waverley Viscount Waverley Crossbench

To ask Her Majesty's Government what assessment they have made of how many treatments for rare diseases are available in Scotland that are unavailable in England.

Photo of Viscount Waverley Viscount Waverley Crossbench

To ask Her Majesty's Government what assessment they have made of the sustainability of the NICE appraisal process for rare disease medicines that do not meet the highly specialised technology criteria.

Photo of Lord O'Shaughnessy Lord O'Shaughnessy The Parliamentary Under-Secretary for Health and Social Care

With the aim of improving the lives of all those affected by a rare disease, the United Kingdom Government published The UK Strategy for Rare Diseases in 2013, a high-level framework containing 51 commitments which sets out a seven-year strategic vision from 2013-2020. A copy of the Strategy is attached. The Government is committed to implementing the Strategy’s commitments and has, in January 2018, published two implementation plans setting out its actions for England. Copies of the Department’s The UK Strategy for Rare Diseases: Rare Diseases implementation plan for England and NHS England’s Implementation Plan for the UK Strategy for Rare Diseases are attached.

The Government has not made any assessment of differences in access to medicines for the treatment of rare diseases or on the available number of treatments between England, the devolved administrations and economically similar countries in Europe.

With regard to the Government’s assessment of the sustainability of the National Institute for Health and Care Excellence’s (NICE) appraisal process for rare disease medicines that do not meet the highly specialised technology criteria, patients with rare diseases in England benefit from the same NHS Constitution right to clinically and cost-effective medicines as patients with more common conditions. NICE has recommended a number of medicines for the treatment of rare diseases through its technology appraisal and highly specialised technology evaluation programmes which are now routinely available to National Health Service patients in line with NICE’s recommendations.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.